Advances in Immunotherapy in Esophagogastric Cancer
Immune checkpoint inhibitors are rapidly transforming the care of patients with esophagogastric cancer. Particularly, anti-PD-1 therapy has demonstrated promising efficacy in metastatic and resectable disease. In this review, the authors discuss landmark clinical trials, highlight challenges and opportunities in this field, and propose potential directions for future work.
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Khalid Jazieh, Harry Yoon, Mojun Zhu Source Type: research